Pharmaceutical Fine Chemicals Market

Market Overview:

The global pharmaceutical fine chemicals market size reached US$ 132.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 195.3 Billion by 2028, exhibiting a growth rate (CAGR) of 6.42% during 2023-2028.

Fine chemicals refer to a set of pure and complex chemicals that are manufactured in limited quantities at higher prices. They are produced in multipurpose plants with the support of a multistep batch biotechnological method. Unlike specialty chemicals, these substances are accumulated precisely based on their distinct functional characteristics and specific molecular properties. After collection, fine chemicals are used as key agents, stabilizers, and solvents for producing several pharmaceutical chemical products, including magnesium stearate and gelatin. At present, they are commercially available in proprietary and non-proprietary variants.

Pharmaceutical Fine Chemicals Market Trends:

The increasing prevalence of various neurological and cardiovascular diseases, including arrhythmias, stroke, cancer, and coronary artery ailments, especially amongst the geriatric population, is one of the prime factors driving the pharmaceutical fine chemical market toward growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel vaccines, drugs, and pharmaceutical medications for retaliating against coronavirus diseases (COVID-19) and several other disorders is further facilitating the widespread adoption of these medications in the healthcare sector. This, in turn, is acting as another growth-inducing factor in the market. Additionally, enforcement of different guidelines for utilizing pharmaceutical fine chemicals as raw materials to manufacture medicines, while meeting the quality standards is contributing to the market growth. Other factors, such as significant expansion in the pharmaceutical industry, increasing investments in the research and development (R&D) activities, and the growing consumer awareness regarding numerous disorders and the available medication options, are creating a positive outlook for the market across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmaceutical fine chemicals market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, product, size and application.

Breakup by Type:

• Proprietary
• Non-proprietary
   

Breakup by Product:

• Active Ingredients
• Basic Building Blocks
• Advanced Intermediates
   

Breakup by Size:

• Big Molecules
• Small Molecules
   

Breakup by Application:

• Cardiovascular
• Neurological
• Oncological
• Respiratory
• Gastrointestinal
• Musculoskeletal
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being BASF SE, Borregaard ASA, CHEMADA Industries Ltd. (Turpaz), Denisco Chemicals Pvt Ltd, Dupont De Nemours Inc., Eastman Chemical Company, Evonik Industries AG, Koninklijke DSM N.V., Lonza Group AG, Solvay S.A., Syntor Fine Chemicals Ltd. (Aceto Corporation) and W. R. Grace and Co. (Standard Industries Inc.).

Report Coverage: